Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) announced its participation in two virtual investor conferences. The Goldman Sachs 41st Annual Global Healthcare Conference will take place on June 9, 2020, at 3:00 p.m. E.T., followed by the BofA Securities Napa Biopharma Conference on June 24, 2020, at 12:30 p.m. E.T. Live webcasts will be available on Sarepta's website and archived for 90 days. Sarepta is a leader in precision genetic medicine, focusing on treatments for rare diseases, including Duchenne muscular dystrophy, with over 40 programs in development.
Sarepta Therapeutics (NASDAQ: SRPT) announced the granting of equity awards to 8 new employees on May 29, 2020, in accordance with its 2014 Employment Commencement Incentive Plan. The awards included options to purchase 8,015 shares of common stock and 4,015 restricted stock units (RSUs). The options have an exercise price of $152.27 per share, matching the closing price on the grant date. Vesting schedules for both options and RSUs are set to complete over four years, contingent on continued employment.
Summary not available.
Summary not available.
Summary not available.